ARCADIA trials: Can nemolizumab be a valid alternative to the therapies currently available?

Med. 2024 Nov 8;5(11):1340-1341. doi: 10.1016/j.medj.2024.09.008.

Abstract

ARCADIA 1 and ARCADIA 2 were two randomized, placebo-controlled phase 3 trials showing the effectiveness of nemolizumab with concomitant use of low-to-medium potency topical corticosteroids, and/or with or without topical calcineurin inhibitors, in adults and adolescents with moderate-to-severe atopic dermatitis. Coprimary endpoints were met in the nemolizumab plus background therapy groups in both trials, with significant differences versus placebo.

Publication types

  • Randomized Controlled Trial
  • Clinical Trial, Phase III

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Antibodies, Monoclonal, Humanized* / pharmacology
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Calcineurin Inhibitors / administration & dosage
  • Calcineurin Inhibitors / pharmacology
  • Calcineurin Inhibitors / therapeutic use
  • Dermatitis, Atopic* / drug therapy
  • Drug Therapy, Combination
  • Humans
  • Male
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Calcineurin Inhibitors
  • Adrenal Cortex Hormones